Prevention and Treatment of Cancer-Related InfectionsPractice Guidelines in Oncology

Patients with cancer are at increased risk for developing infectious complications during the course of their disease and treatment. The following sections of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prevention and Treatment of Cancer-Related Infections provide an overview of the risk factors for infectious complications, recommendations for infectious risk categorization, and strategies for prevention of infections in high-risk patient populations with cancer. Individualized risk evaluation for infections and incorporation of preventative measures are essential components of the overall spectrum of cancer care, and may contribute to optimizing treatment outcomes for patients. (JNCCN 2012;10:1412–1445)

[1]  L. Leibovici,et al.  Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. , 2012, The Cochrane database of systematic reviews.

[2]  W. Leisenring,et al.  Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients. , 2011, Blood.

[3]  S. Belknap,et al.  Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  I. Tan,et al.  Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis , 2011, Annals of Hematology.

[5]  H. Einsele,et al.  Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. , 2011, The Lancet. Infectious diseases.

[6]  H. Einsele,et al.  Testing G-CSF responsiveness predicts the individual susceptibility to infection and consecutive treatment in recipients of high-dose chemotherapy. , 2011, Blood.

[7]  K. Sepkowitz,et al.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  P. Hsueh,et al.  The impact of oral herpes simplex virus infection and candidiasis on chemotherapy-induced oral mucositis among patients with hematological malignancies , 2011, European Journal of Clinical Microbiology & Infectious Diseases.

[9]  J. Dipersio,et al.  Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. , 2010, Blood.

[10]  N. Niitsu,et al.  Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Dimopoulos,et al.  Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem‐cell transplantation: Results of a single institution, randomized phase 2 trial , 2010, American journal of hematology.

[12]  S. Kimura,et al.  Reactivation of hepatitis B virus after rituximab‐containing treatment in patients with CD20‐positive B‐cell lymphoma , 2010, Cancer.

[13]  Y. Kanda,et al.  One‐year low‐dose valacyclovir as prophylaxis for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation. A prospective study of the Japan Hematology and Oncology Clinical Study Group , 2010, Transplant Infectious Disease.

[14]  I. Kerridge,et al.  Pre‐transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy , 2010, Transplant infectious disease : an official journal of the Transplantation Society.

[15]  J. Paues,et al.  Fatal progressive multifocal leukoencephalopathy in a patient with non-Hodgkin lymphoma treated with rituximab. , 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[16]  M. Boccadoro,et al.  Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[17]  M. Cosottini,et al.  Progressive multifocal leukoencephalopathy: a report of three cases in HIV-negative patients with non-Hodgkin's lymphomas treated with rituximab , 2010, Annals of Hematology.

[18]  E. Cowen,et al.  Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity. , 2010, Archives of dermatology.

[19]  Chien-Hung Chen,et al.  Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients , 2010, Annals of Hematology.

[20]  I. Jaiyesimi,et al.  Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia: a report of three cases and review of the literature. , 2010, Clinical lymphoma, myeloma & leukemia.

[21]  J. Wagner,et al.  Impact of cytomegalovirus (CMV) reactivation after umbilical cord blood transplantation. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[22]  H. Einsele,et al.  Vaccination of hematopoietic cell transplant recipients , 2009, Bone Marrow Transplantation.

[23]  C. Viscoli,et al.  Bacterial infection prevention after hematopoietic cell transplantation , 2009, Bone Marrow Transplantation.

[24]  K. Peggs,et al.  Background to hematopoietic cell transplantation, including post transplant immune recovery , 2009, Bone Marrow Transplantation.

[25]  H. Einsele,et al.  Viral disease prevention after hematopoietic cell transplantation , 2009, Bone Marrow Transplantation.

[26]  Hermann Einsele,et al.  Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective , 2009, Biology of Blood and Marrow Transplantation.

[27]  C. Ukomadu,et al.  Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[28]  R. Schlenk,et al.  Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  N. Cox,et al.  Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. , 2009 .

[30]  E. Mylonakis,et al.  Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance , 2009, Haematologica.

[31]  M. Sanz,et al.  Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[32]  David Green,et al.  Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. , 2009, Blood.

[33]  R. Liang.  How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. , 2009, Blood.

[34]  T. Buchler,et al.  Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib. , 2009, Clinical lymphoma & myeloma.

[35]  M. Ghany,et al.  Diagnosis, management, and treatment of hepatitis C: An update , 2009, Hepatology.

[36]  E. Anaissie,et al.  Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  T. Abel,et al.  Progressive multifocal leukoencephalopathy in a patient with follicular lymphoma treated with multiple courses of rituximab , 2009, Leukemia & lymphoma.

[38]  A. Cross,et al.  Early hepatitis B virus DNA reduction in hepatitis B e antigen–positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir , 2009, Hepatology.

[39]  G. Krishna,et al.  Pharmacokinetics and Absorption of Posaconazole Oral Suspension under Various Gastric Conditions in Healthy Volunteers , 2008, Antimicrobial Agents and Chemotherapy.

[40]  Huy Trinh,et al.  Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. , 2008, The New England journal of medicine.

[41]  G. Papanicolaou,et al.  Risk factors for late Staphylococcus aureus bacteremia after allogeneic hematopoietic stem cell transplantation: a single-institution, nested case-controlled study. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[42]  T. Sauerbruch,et al.  Fatal acute liver failure due to reactivation of hepatitis B following treatment with fludarabine/cyclophosphamide/rituximab for low grade non-Hodgkin's lymphoma. , 2008, European journal of medical research.

[43]  K. Tobinai,et al.  Progressive multifocal leukoencephalopathy in a patient with B-cell lymphoma during rituximab-containing chemotherapy: case report and review of the literature , 2008, International journal of hematology.

[44]  S. Trudel,et al.  Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  R. Neuwirth,et al.  Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  C. Solano,et al.  Quantification of DNA in Plasma by an Automated Real-Time PCR Assay (Cytomegalovirus PCR Kit) for Surveillance of Active Cytomegalovirus Infection and Guidance of Preemptive Therapy for Allogeneic Hematopoietic Stem Cell Transplant Recipients , 2008, Journal of Clinical Microbiology.

[47]  R. Vij,et al.  Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. , 2008, Blood.

[48]  H. Nakasone,et al.  Long‐term ultra‐low‐dose acyclovir against varicella‐zoster virus reactivation after allogeneic hematopoietic stem cell transplantation , 2007, American journal of hematology.

[49]  J. Perfect.  Aerosolized antifungal prophylaxis: the winds of change? , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[50]  W. Hop,et al.  Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[51]  Yong Park,et al.  Hepatitis B virus reactivation in a surface antigen-negative and antibody-positive patient after rituximab plus CHOP chemotherapy. , 2008, Cancer research and treatment : official journal of Korean Cancer Association.

[52]  H. Kantarjian,et al.  Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. , 2008, Blood.

[53]  M. Klimpfinger,et al.  Progressive multifocal leukoencephalopathy after rituximab in a patient with relapsed follicular lymphoma and low IgG levels and a low CD4+ lymphocyte count , 2008, Leukemia & lymphoma.

[54]  T. Robak,et al.  Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  P. Marcellin,et al.  Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. , 2007, Annals of internal medicine.

[56]  Lucinda J Billingham,et al.  Rational selection of patients for antibacterial prophylaxis after chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  R. Bouabdallah,et al.  JC papovavirus leukoencephalopathy after first line treatment with CHOP and rituximab , 2007, Haematologica.

[58]  L. Leibovici,et al.  Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. , 2007, Mayo Clinic proceedings.

[59]  Susan J. Lindemulder,et al.  Successful Intermittent Prophylaxis With Trimethoprim/Sulfamethoxazole 2 Days per Week for Pneumocystis carinii (jiroveci) Pneumonia in Pediatric Oncology Patients , 2007, Pediatrics.

[60]  F. Locatelli,et al.  Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation , 2007, Transplant infectious disease : an official journal of the Transplantation Society.

[61]  A. Wald,et al.  One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. , 2007, Blood.

[62]  Y. Li,et al.  The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients , 2007, American journal of hematology.

[63]  C. Pui,et al.  Prophylaxis of Pneumocystis carinii pneumonia with atovaquone in children with leukemia , 2007, Cancer.

[64]  M. Whitby,et al.  Severe photosensitivity causing multifocal squamous cell carcinomas secondary to prolonged voriconazole therapy. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[65]  R. Champlin,et al.  Streptococcus pneumoniae Infections in 47 Hematopoietic Stem Cell Transplantation Recipients: Clinical Characteristics of Infections and Vaccine-Breakthrough Infections, 1989-2005 , 2007, Medicine.

[66]  M. Varettoni,et al.  Late onset of bortezomib-associated cutaneous reaction following herpes zoster , 2007, Annals of Hematology.

[67]  J. Lipton,et al.  Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. , 2007, The New England journal of medicine.

[68]  J. Perfect,et al.  Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. , 2007, The New England journal of medicine.

[69]  D. Holbert,et al.  Effect of reduction in ciprofloxacin use on prevalence of meticillin-resistant Staphylococcus aureus rates within individual units of a tertiary care hospital. , 2006, The Journal of hospital infection.

[70]  Larry K. Pickering,et al.  General recommendations on immunization --- recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2006, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[71]  M. Ciotti,et al.  A prospective study comparing quantitative Cytomegalovirus (CMV) polymerase chain reaction in plasma and pp65 antigenemia assay in monitoring patients after allogeneic stem cell transplantation , 2006, BMC infectious diseases.

[72]  L. Leibovici,et al.  Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis. , 2006, The Journal of antimicrobial chemotherapy.

[73]  Atlanta,et al.  Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. , 2006, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[74]  M. Keating,et al.  Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. , 2006, Clinical lymphoma & myeloma.

[75]  Judith A. Smith,et al.  Evaluation of vaccine dosing in patients with solid tumors receiving myelosuppressive chemotherapy , 2006, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[76]  H. Einsele,et al.  Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[77]  L. Shaw,et al.  Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[78]  J. Perkins,et al.  Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation , 2006, Bone Marrow Transplantation.

[79]  D. Skiest,et al.  A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[80]  R. Willemze,et al.  Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients , 2006, Bone Marrow Transplantation.

[81]  P. Lampertico,et al.  Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H. , 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[82]  H. Einsele,et al.  Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. , 2006, Blood.

[83]  M. Boeckh,et al.  Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation--a randomized double-blind placebo-controlled study. , 2006, Blood.

[84]  J. Wingard,et al.  Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[85]  H. Prince,et al.  Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab * , 2006, British journal of haematology.

[86]  Stuart Johnson,et al.  An epidemic, toxin gene-variant strain of Clostridium difficile. , 2005, The New England journal of medicine.

[87]  J. Bartlett,et al.  The new Clostridium difficile--what does it mean? , 2005, The New England journal of medicine.

[88]  Ken Dewar,et al.  A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. , 2005, The New England journal of medicine.

[89]  R. Foà,et al.  Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. , 2005, The New England journal of medicine.

[90]  R. Huddart,et al.  Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. , 2005, The New England journal of medicine.

[91]  J. Tarrand,et al.  Streptococcus pneumoniae Bacteremia in Patients With Cancer: Disease Characteristics and Outcomes in the Era of Escalating Drug Resistance (1998-2002) , 2005, Medicine.

[92]  B. Storer,et al.  Toxicity and efficacy of daily dapsone as Pneumocystis jiroveci prophylaxis after hematopoietic stem cell transplantation: a case-control study. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[93]  L. Leibovici,et al.  Meta-Analysis: Antibiotic Prophylaxis Reduces Mortality in Neutropenic Patients , 2005, Annals of Internal Medicine.

[94]  C. Fegan,et al.  Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  M. Montillo,et al.  Eradication of Minimal Residual Disease with Alemtuzumab in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients: The Need for a Standard Method of Detection and the Potential Impact of Bone Marrow Clearance on Disease Outcome , 2005, Cancer investigation.

[96]  J. Lipton,et al.  Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[97]  Steven D. Brown,et al.  Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001-2002, as part of the PROTEKT US study. , 2004, The Journal of antimicrobial chemotherapy.

[98]  K. Rolston.  The Infectious Diseases Society of America 2002 guidelines for the use of antimicrobial agents in patients with cancer and neutropenia: salient features and comments. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[99]  R. Storb,et al.  Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[100]  J. Byrd,et al.  Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. , 2004, Clinical lymphoma.

[101]  W. Leisenring,et al.  Cyclophosphamide metabolism is affected by azole antifungals. , 2004, Blood.

[102]  W. Leisenring,et al.  Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. , 2004, Blood.

[103]  S. Riddell,et al.  Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. , 2003, Blood.

[104]  C. Bridges,et al.  Using live, attenuated influenza vaccine for prevention and control of influenza: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2003, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[105]  E. Thiel,et al.  Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. , 2003, Blood.

[106]  J. Epstein,et al.  Oral candidiasis in hematopoietic cell transplantation patients: an outcome-based analysis. , 2003, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[107]  M. Territo,et al.  Intravenous and Oral Itraconazole versus Intravenous and Oral Fluconazole for Long-Term Antifungal Prophylaxis in Allogeneic Hematopoietic Stem-Cell Transplant Recipients: A Multicenter, Randomized Trial , 2003, Annals of Internal Medicine.

[108]  M. Boeckh,et al.  Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. , 2002, Blood.

[109]  S. Fook-Chong,et al.  Randomized trial of fluconazole versus low‐dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation , 2002, American journal of hematology.

[110]  S. Rowland-Jones,et al.  Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells. , 2002, Blood.

[111]  L. Verdonck,et al.  Influence of cytomegalovirus seropositivity on outcome after T cell-depleted bone marrow transplantation: contrasting results between recipients of grafts from related and unrelated donors. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[112]  W. Leisenring,et al.  Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. , 2002, Blood.

[113]  Theresa Hahn,et al.  Efficacy of High-Efficiency Particulate Air Filtration in Preventing Aspergillosis in Immunocompromised Patients With Hematologic Malignancies , 2002, Infection Control & Hospital Epidemiology.

[114]  D. Fong,et al.  Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation , 2002, Hepatology.

[115]  S. Coutre,et al.  Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia. , 2002, Clinical lymphoma.

[116]  J. Lipton,et al.  Aerosolized pentamidine prophylaxis for Pneumocystis carinii pneumonia after allogeneic marrow transplantation , 2002, Transplant infectious disease : an official journal of the Transplantation Society.

[117]  Robin Patel,et al.  Bacteremia due to viridans group Streptococci with diminished susceptibility to Levofloxacin among neutropenic patients receiving levofloxacin prophylaxis. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[118]  J. Byrd,et al.  Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. , 2002, Blood.

[119]  M. Boeckh,et al.  Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[120]  P. Ljungman,et al.  Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation survey , 2002, British journal of haematology.

[121]  P. Ljungman,et al.  Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. , 2002, Blood.

[122]  J. Byrd,et al.  Frequency and type of serious infections in fludarabine‐refractory B‐cell chronic lymphocytic leukemia and small lymphocytic lymphoma , 2002, Cancer.

[123]  D. Kontoyiannis,et al.  The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. , 2002, The American journal of medicine.

[124]  T. Calandra,et al.  Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer , 2002 .

[125]  H. Einsele,et al.  Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. , 2002, Blood.

[126]  B. McMahon,et al.  Chronic hepatitis B , 2001, Hepatology.

[127]  P. Ljungman.  Respiratory virus infections in stem cell transplant patients: the European experience. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[128]  D. Milligan,et al.  Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections , 2001, Bone Marrow Transplantation.

[129]  F. Prósper,et al.  Qualitative Plasma PCR Assay (AMPLICOR CMV Test) versus pp65 Antigenemia Assay for Monitoring Cytomegalovirus Viremia and Guiding Preemptive Ganciclovir Therapy in Allogeneic Stem Cell Transplantation , 2001, Journal of Clinical Microbiology.

[130]  G. Rossi,et al.  Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy , 2001, British journal of haematology.

[131]  D. Bates,et al.  Correlates of acute renal failure in patients receiving parenteral amphotericin B. , 2001, Kidney international.

[132]  C. Tournay,et al.  Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. , 2001, Blood.

[133]  R. Larson,et al.  Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[134]  G. Ehninger,et al.  SUCCESSFUL PREEMPTIVE CIDOFOVIR TREATMENT FOR CMV ANTIGENEMIA AFTER DOSE-REDUCED CONDITIONING AND ALLOGENEIC BLOOD STEM CELL TRANSPLANTATION , 2001, Transplantation.

[135]  F. Spijkervet,et al.  Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[136]  H. Einsele,et al.  Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. , 2001, Blood.

[137]  I. Dervite,et al.  Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. , 2001, The New England journal of medicine.

[138]  W. Yeo,et al.  Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors , 2000, Journal of medical virology.

[139]  M. Boeckh,et al.  Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. , 2000, Blood.

[140]  S. Singhal,et al.  Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants. , 2000, Blood.

[141]  G. Buchanan,et al.  Feasibility of oral ciprofloxacin for the outpatient management of febrile neutropenia in selected children with cancer , 2000, Cancer.

[142]  E. Anaissie,et al.  Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[143]  S. Crawford,et al.  High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[144]  L. Constine,et al.  Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[145]  M. Paesmans,et al.  Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. , 1999, The New England journal of medicine.

[146]  J. Tarrand,et al.  Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[147]  E. Bow,et al.  Randomized Placebo-Controlled Trial of Fluconazole Prophylaxis for Neutropenic Cancer Patients: Benefit Based on Purpose and Intensity of Cytotoxic Therapy , 1999 .

[148]  W. El-Sadr,et al.  Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. , 1998, The New England journal of medicine.

[149]  E. Anaissie,et al.  Infections in Patients with Chronic Lymphocytic Leukemia Treated with Fludarabine , 1998, Annals of Internal Medicine.

[150]  C. Rieux,et al.  Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. , 1998, Transplantation.

[151]  W. Hiddemann,et al.  Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia , 1998, Cancer.

[152]  T. Lamparelli,et al.  Foscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study , 1998, Bone Marrow Transplantation.

[153]  S. Sonis,et al.  The impact of mucositis on α‐hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies , 1998, Cancer.

[154]  D. De Bacquer,et al.  Impact of previous aspergillosis on the outcome of bone marrow transplantation. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[155]  J. Lau,et al.  Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[156]  R. Bowden,et al.  Respiratory virus infections after marrow transplant: the Fred Hutchinson Cancer Research Center experience. , 1997, The American journal of medicine.

[157]  L. Bergmann,et al.  Itraconazole for prophylaxis of systemic mycoses in neutropenic patients with haematological malignancies. , 1996, The Journal of antimicrobial chemotherapy.

[158]  E. Rubenstein,et al.  Early empiric antibiotic therapy for febrile neutropenia patients at low risk. , 1996, Infectious disease clinics of North America.

[159]  R. Couch,et al.  Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[160]  E. González-Barca,et al.  Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution , 1996, European Journal of Clinical Microbiology and Infectious Diseases.

[161]  P. Pizzo,et al.  Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia , 1995, Cancer.

[162]  M. Putti,et al.  High-dose cytosine arabinoside and viridans streptococcus sepsis in children with leukemia. , 1995, Pediatric hematology and oncology.

[163]  M. Levenstein,et al.  Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study. , 1995, The Journal of infectious diseases.

[164]  R. Couch,et al.  Epidemiology of Influenza A virus infection in patients with acute or chronic leukemia , 1995, Supportive Care in Cancer.

[165]  P. Francioli,et al.  Bacteremia due to viridans streptococci in neutropenic patients: a review. , 1994, The American journal of medicine.

[166]  F. Mandelli,et al.  Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation , 1994, The Lancet.

[167]  K. Sepkowitz.  Pneumocystis carinii pneumonia in patients without AIDS. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[168]  E. Estey,et al.  Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. , 1993, Blood.

[169]  P. Pizzo,et al.  Management of fever in patients with cancer and treatment-induced neutropenia. , 1993, The New England journal of medicine.

[170]  H. Horowitz,et al.  Fluconazole Prophylaxis of Fungal Infections in Patients with Acute Leukemia: Results of a Randomized Placebo-Controlled, Double-Blind, Multicenter Trial , 1993, Annals of Internal Medicine.

[171]  E. Anaissie,et al.  Listeriosis in Patients with Chronic Lymphocytic Leukemia Who Were Treated with Fludarabine and Prednisone , 1992, Annals of Internal Medicine.

[172]  H. Chapel,et al.  Predictors of infection in chronic lymphocytic leukaemia (CLL) , 1992, Clinical and experimental immunology.

[173]  K. Sepkowitz.  Pneumocystis carinii pneumonia among patients with neoplastic disease. , 1992, Seminars in respiratory infections.

[174]  L. Elting,et al.  Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[175]  Z. Abbas,et al.  Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients , 1992, The Lancet.

[176]  J. L. Goodman,et al.  A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. , 1992, The New England journal of medicine.

[177]  K. Sepkowitz,et al.  Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. , 1992, JAMA.

[178]  R. Finberg,et al.  Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[179]  S. Steinberg,et al.  Patterns of Infection in Patients with Aplastic Anemia and the Emergence of Aspergillus As a Major Cause of Death , 1992, Medicine.

[180]  K. Sepkowitz,et al.  Pneumocystis carinii pneumonia developing within one month of intensive chemotherapy for treatment of acute lymphoblastic leukemia. , 1991, The New England journal of medicine.

[181]  P. Kalhs,et al.  Functional asplenia after bone marrow transplantation. , 1990, Annals of internal medicine.

[182]  S. Piantadosi,et al.  Herpes zoster infection after autologous bone marrow transplantation , 1989 .

[183]  R. Mayer,et al.  The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. , 1988, Archives of internal medicine.

[184]  T. Louie,et al.  Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia. The trade-off for reduced gram-negative sepsis. , 1988, The American journal of medicine.

[185]  M. Thornquist,et al.  Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. , 1988, The New England journal of medicine.

[186]  M. Schell,et al.  Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. , 1987, The New England journal of medicine.

[187]  C. Hall,et al.  INFLUENZA IN CHILDREN WITH CANCER , 1987, Pediatric Research.

[188]  Schimpff Sc.  Empiric antibiotic therapy for granulocytopenic cancer patients. , 1986 .

[189]  J. Wands,et al.  Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen. , 1985, The New England journal of medicine.

[190]  B. Strom,et al.  Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. , 1984, Annals of internal medicine.

[191]  D. Griffin,et al.  Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study. , 1983, Annals of internal medicine.

[192]  O. Laskin,et al.  Acyclovir prophylaxis of herpes-simplex-virus infections. , 1981, The New England journal of medicine.

[193]  N. Flournoy,et al.  Infection with herpes simplex virus and cell-mediated immunity after marrow transplant. , 1980, The Journal of infectious diseases.

[194]  S. Feig,et al.  Pneumococcal infections after human bone-marrow transplantation. , 1979, Annals of internal medicine.

[195]  R. Aur,et al.  Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. , 1977, The New England journal of medicine.

[196]  C. Presant,et al.  Influenza immunization of adult patients with malignant diseases. , 1977, Annals of internal medicine.

[197]  R. Webster,et al.  Influenza in children and young adults with cancer. 20 cases , 1977, Cancer.

[198]  Y. S. Sathe,et al.  Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. , 1966, Annals of internal medicine.

[199]  F. Zoulim,et al.  Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT , 2011, Bone Marrow Transplantation.

[200]  S. Arron,et al.  Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. , 2010, Journal of the American Academy of Dermatology.

[201]  S. Singhal,et al.  Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy , 2009, Cancer.

[202]  Y. Hiasa,et al.  Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. , 2006, Internal medicine.

[203]  C. Klersy,et al.  Multiple lines of chemotherapy are the main risk factor for severe infections in patients with chronic lymphocytic leukemia with febrile episodes. , 2005, Haematologica.

[204]  P. Chiusolo,et al.  Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir. , 2004, Haematologica.

[205]  R. Rubin,et al.  Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. , 2004, Gastroenterology.

[206]  A. Bosi,et al.  Polymerase chain reaction-based "pre-emptive" therapy with cidofovir for cytomegalovirus reactivation in allogeneic hematopoietic stem cells transplantation recipients: a prospective study. , 2002, Haematologica.

[207]  K. Sepkowitz,et al.  Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. , 2001, Hematology. American Society of Hematology. Education Program.

[208]  M. Vasconcelles,et al.  Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections. , 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[209]  T. C. White,et al.  Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. , 2000, The Journal of infectious diseases.

[210]  R. García-Carbonero,et al.  Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever , 1999, Cancer.

[211]  H. Prentice,et al.  Clinical strategies for the management of cytomegalovirus infection and disease in allogeneic bone marrow transplant , 1997, Bone Marrow Transplantation.

[212]  DiNubile Mj.  Fever and neutropenia: still a challenge. , 1995 .

[213]  S. Steinberg,et al.  Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[214]  A. Nagler,et al.  Cytosine arabinoside as a major risk factor for Streptococcus viridans septicemia following bone marrow transplantation: a 5-year prospective study. , 1995, Bone marrow transplantation.

[215]  R. Finberg,et al.  Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[216]  D. Savage,et al.  Biphasic pattern of bacterial infection in multiple myeloma. , 1982, Annals of internal medicine.